Exploring the current landscape of single‐cell RNA sequencing applications in gastric cancer research
Journal of Cellular and Molecular Medicine · 2024-04 · 28 (7)
DOI: 10.1111/jcmm.18159 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 17.03.2024. Verfasst von Wireko Andrew Awuah und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Sumy State University, Sumy, Ukraine. Hauptthemen laut MEDLINE: Stomach Neoplasms, Biomedical Research. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Gastric cancer (GC) represents a major global health burden and is responsible for a significant number of cancer‐related fatalities. Its complex nature, characterized by heterogeneity and aggressive behaviour, poses considerable challenges for effective diagnosis and treatment. Single‐cell RNA sequencing (scRNA‐seq) has emerged as an important technique, offering unprecedented precision and depth in gene expression profiling at the cellular level. By facilitating the identification of distinct cell populations, rare cells and dynamic transcriptional changes within GC, scRNA‐seq has yielded valuable insights into tumour progression and potential therapeutic targets. Moreover, this technology has significantly improved our comprehension of the tumour microenvironment (TME) and its intricate interplay with immune cells, thereby opening avenues for targeted therapeutic strategies. Nonetheless, certain obstacles, including tumour heterogeneity and technical limitations, persist in the field. Current endeavours are dedicated to refining protocols and computational tools to surmount these challenges. In this narrative review, we explore the significance of scRNA‐seq in GC, emphasizing its advantages, challenges and potential applications in unravelling tumour heterogeneity and identifying promising therapeutic targets. Additionally, we discuss recent developments, ongoing efforts to overcome these challenges, and future prospects. Although further enhancements are required, scRNA‐seq has already provided valuable insights into GC and holds promise for advancing biomedical research and clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, Sumy State University, Sumy, Ukraine.
- School of Medicine, Queen's University Belfast, Belfast, UK.
- Faculty of Medicine, University of St Andrews, St Andrews, UK.
- Department of Oncology & Metabolism, The University of Sheffield, Sheffield, UK.
- Department of Clinical Neurosciences, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
- Faculty of Medicine, Bangalore Medical College and Research Institute, Bangalore, Karnataka, India.
ORCID-Profile: Sakshi Roy, Joecelyn Kirani Tan, Zekai Qiang
Zitieren
APA
Awuah, W. A., Roy, S., Tan, J. K., Adebusoye, F. T., Qiang, Z., Ferreira, T., Ahluwalia, A., Shet, V., Yee, A. L. W., Abdul-Rahman, T., & Papadakis, M. (2024). Exploring the current landscape of single‐cell RNA sequencing applications in gastric cancer research. Journal of Cellular and Molecular Medicine, 28(7). https://doi.org/10.1111/jcmm.18159
Vancouver
Awuah WA, Roy S, Tan JK, Adebusoye FT, Qiang Z, Ferreira T, et al. Exploring the current landscape of single‐cell RNA sequencing applications in gastric cancer research. Journal of Cellular and Molecular Medicine. 2024;28(7). doi:10.1111/jcmm.18159
BibTeX
@article{Awuah2024,
author = {Awuah, Wireko Andrew and Roy, Sakshi and Tan, Joecelyn Kirani and Adebusoye, Favour Tope and Qiang, Zekai and Ferreira, Tomas and Ahluwalia, Arjun and Shet, Vallabh and Yee, Amanda Leong Weng and Abdul-Rahman, Toufik and Papadakis, Marios},
title = {Exploring the current landscape of single‐cell RNA sequencing applications in gastric cancer research},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
volume = {28},
number = {7},
doi = {10.1111/jcmm.18159}
}
EUVIMED